靶向 1 型糖尿病中的晚期糖基化终产物受体（RAGE）。

Targeting the receptor for advanced glycation end products (RAGE) in type 1 diabetes.

机构信息

Glycation and Diabetes, Translational Research Institute (TRI), Mater Research Institute-The University of Queensland (MRI-UQ), Brisbane, Queensland, Australia.

School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia.

出版信息

Med Res Rev. 2020 Jul;40(4):1200-1219. doi: 10.1002/med.21654. Epub 2020 Feb 28.

DOI:10.1002/med.21654

PMID:32112452

Abstract

Type 1 diabetes (T1D) is one of the most common chronic diseases manifesting in early life, with the prevalence increasing worldwide at a rate of approximately 3% per annum. The prolonged hyperglycaemia characteristic of T1D upregulates the receptor for advanced glycation end products (RAGE) and accelerates the formation of RAGE ligands, including advanced glycation end products, high-mobility group protein B1, S100 calcium-binding proteins, and amyloid-beta. Interestingly, changes in the expression of RAGE and these ligands are evident in patients before the onset of T1D. RAGE signals via various proinflammatory cascades, resulting in the production of reactive oxygen species and cytokines. A large number of proinflammatory ligands that can signal via RAGE have been implicated in several chronic diseases, including T1D. Therefore, it is unsurprising that RAGE has become a potential therapeutic target for the treatment and prevention of disease. In this review, we will explore how RAGE might be targeted to prevent the development of T1D.

摘要

1 型糖尿病（T1D）是一种最常见的幼年起病的慢性疾病，其全球患病率正以每年约 3%的速度递增。T1D 患者的长期高血糖会使晚期糖基化终产物受体（RAGE）上调，并加速 RAGE 配体的形成，包括晚期糖基化终产物、高迁移率族蛋白 B1、S100 钙结合蛋白和淀粉样β。有趣的是，在 T1D 发病前，患者体内 RAGE 及其配体的表达就发生了变化。RAGE 通过多种促炎级联反应信号转导，导致活性氧和细胞因子的产生。大量可通过 RAGE 信号转导的促炎配体已被牵涉到多种慢性疾病中，包括 T1D。因此，RAGE 成为治疗和预防疾病的潜在治疗靶点并不令人意外。在这篇综述中，我们将探讨如何靶向 RAGE 以预防 T1D 的发生。